As countermeasure, therapeutic PPARα/γ activation reprograms in context with the concerted activity profile of tumor tissue editing approaches hallmarks of cancer, represses important transcription factors, like STAT3, NF-kB, AP-1, PI3K/Akt, HIF1α and NFAT and decreases the expression of TNF-α, TGF-β, IL-6, IL-8, VEGF, iNOS, as indicated by preclinical data (40, 74–76). The gene discussed is PPARA; the disease is neoplasm.